BC030476 Inhibitors
Chemical inhibitors of BC030476 can influence its activity by targeting various signaling pathways that are essential for its function. PD98059 and U0126 are both inhibitors of MEK, an upstream activator of ERK within the MAPK signaling pathway. By preventing the phosphorylation and activation of ERK, these inhibitors can effectively disrupt the downstream signaling that leads to the activation of BC030476. Similarly, LY294002 and Wortmannin function by inhibiting PI3K, thereby blocking the PI3K/Akt pathway, which is known to be crucial for the function of BC030476. The inhibition of PI3K by these chemicals results in a reduction of PIP3 levels and subsequent Akt signaling, culminating in decreased activity of BC030476. Rapamycin takes a slightly different approach by specifically targeting mTOR, a downstream component of the PI3K/Akt pathway, further hindering the pathway and limiting the functional capabilities of BC030476.
Further inhibitory effects on BC030476 can be achieved through chemicals such as SP600125, SB203580, and ZM447439. SP600125 targets the JNK pathway, another branch of the MAPK signaling pathways, thus preventing the activation of BC030476 through this route. SB203580 selectively inhibits p38 MAP kinase, which is another MAPK pathway component, and its inhibition can decrease BC030476 activity. ZM447439 aims at the cell cycle control mechanism by inhibiting Aurora kinases, which can impair BC030476 function associated with cell cycle progression. In addition to these, Dasatinib and PP2 are kinase inhibitors that target Bcr-Abl, Src family kinases, and others within their spectrum, leading to the inhibition of BC030476 activity by blocking the activation signals that pass through these kinases. Lestaurtinib inhibits JAK2, impacting BC030476 activity in the signaling pathways regulated by JAK2. Lastly, Sorafenib, by targeting multiple kinases including Raf kinases and receptor tyrosine kinases, can inhibit the activation and function of BC030476 by interfering with the signaling pathways that these kinases regulate. Each chemical, through its unique mechanism, contributes to the comprehensive inhibition of BC030476 by targeting different molecules within the signaling networks that control its activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a specific inhibitor of mitogen-activated protein kinase kinase (MEK), which is upstream of extracellular signal-regulated kinases (ERKs). By inhibiting MEK, the subsequent activation of ERK is prevented. As BC030476 is part of the ERK pathway, inhibition of this pathway upstream would lead to a decrease in BC030476 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is an inhibitor of phosphoinositide 3-kinases (PI3K), thereby preventing the production of phosphatidylinositol (3,4,5)-triphosphate (PIP3) and subsequent activation of Akt. Given that BC030476 is involved in the PI3K/Akt pathway, its inhibition by LY294002 would result in decreased BC030476 function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is an irreversible PI3K inhibitor, which leads to the inhibition of Akt signaling. As BC030476 activity is contingent upon the PI3K/Akt pathway, the inhibition of this pathway by Wortmannin would lead to the suppression of BC030476 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin selectively inhibits the mTOR (mammalian target of rapamycin), which is a key component of the PI3K/Akt/mTOR pathway. Inhibition of mTOR would disrupt downstream signaling required for BC030476's activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), part of the MAPK signaling pathways. By inhibiting JNK, SP600125 would prevent activation of downstream proteins, including BC030476. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. Inhibition of p38 MAPK by SB203580 would lead to functional inhibition of downstream proteins, including BC030476, which is part of this signaling pathway. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $150.00 $349.00 | 15 | |
ZM447439 specifically inhibits Aurora kinases, which are essential for cell cycle progression. As BC030476 is associated with cell cycle control, inhibition of Aurora kinases by ZM447439 would impair the function of BC030476. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib broadly inhibits Bcr-Abl and Src family kinases. Since BC030476 is involved in signaling pathways that include these kinases, Dasatinib would inhibit the activation of BC030476 through these pathways. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. By inhibiting Src kinases, PP2 prevents the activation of downstream signaling pathways that would otherwise contribute to BC030476 activity. | ||||||
Lestaurtinib | 111358-88-4 | sc-218657 sc-218657A sc-218657B | 1 mg 5 mg 10 mg | $270.00 $320.00 $600.00 | 3 | |
Lestaurtinib inhibits Janus kinase 2 (JAK2), which is involved in various signaling pathways, including those regulating BC030476. Inhibition of JAK2 by Lestaurtinib would decrease the functional activity of BC030476. | ||||||